Lupus erythematosus
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Yana bayyana azaman erythema mai ɗanɗano kaɗan.
Kurwar malam buɗe ido wanda yawanci ke bayyana a fuska.
References
Ganewa da rarraba cutaneous lupus erythematosus (CLE) yana haifar da ƙalubalen bincike, bambanta shi daga systemic lupus erythematosus tare da shigar fata. Binciken na baya-bayan nan ya ba da haske kan kwayoyin halitta, muhalli, da abubuwan rigakafi da ke ƙarƙashin CLE. Shigar da ƙwayoyi musamman ya fito a matsayin ɗaya daga cikin mahimman abubuwan da ke haifar da CLE. Jiyya ya haɗa da hanyoyin kwantar da hankali da na tsari, gami da ƙwararrun ilimin halitta (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , tare da ingantaccen inganci a cikin gwaji na asibiti.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) yana rufe batutuwan fata daban-daban, wasu daga cikinsu na iya haɗawa da manyan matsalolin lafiya. An kasafta shi zuwa nau'i daban-daban, kamar acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE ya ƙunshi discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus rukuni ne na cututtukan cututtukan da ke shafar sassan jiki daban-daban. Wasu nau'ikan, kamar systemic lupus erythematosus (SLE) , suna tasiri ga gabobin jiki da yawa, yayin da wasu, kamar cutaneous lupus erythematosus (CLE) , galibi suna shafar fata. Mun rarraba nau'ikan CLE daban-daban bisa ga cakuda alamun asibiti, gwajin nama, da gwajin jini, amma akwai bambanci da yawa tsakanin mutane. Matsalolin fata sukan tasowa saboda dalilai kamar fallasa hasken rana, shan taba, ko wasu magunguna.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Dalilin lupus erythematosus bai bayyana ba. Daga cikin tagwaye iri daya, idan daya ya shafa akwai damar 24% dayan kuma zai kasance. An yi imanin cewa hormones na jima'i na mata, hasken rana, shan taba, rashi bitamin D, da wasu cututtuka na iya kara haɗari.
Magani na iya haɗawa da NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, da methotrexate. Kodayake corticosteroids suna da tasiri, amfani da dogon lokaci yana haifar da sakamako masu illa.